Background {#Sec1}
==========

In patients undergoing total knee or hip arthroplasty (TKA/THA) for osteoarthritis (OA) postoperative physiotherapy (PPT) is a recommended treatment \[[@CR1]--[@CR4]\]. Several studies have demonstrated its effectiveness in improving function, range of motion and quality of life \[[@CR5]--[@CR8]\]. Moreover, PPT also seems to play an important role in achieving functional independence such as return to work \[[@CR9], [@CR10]\].

Despite the current evidence, there is no consensus on the optimal composition of the treatment, timing (when to start and stop), and dosage (frequency). This has led to considerable practice variation, as demonstrated by a number of studies \[[@CR11]--[@CR13]\]. For instance, a Dutch multicenter study on 522 TKA and THA patients found variation in the use of active and passive treatment modalities, and large individual differences in duration of treatment \[[@CR14]\]. Potential sources of variation are constituted by different postoperative treatment protocols used by orthopedic surgeons and hospital physio therapists (PTs) \[[@CR15]\], as well as variation among primary care PTs delivering the intervention. About 1.66 and 1.26 per 1000 people receive TKA or THA respectively in western countries each year \[[@CR16]\]. From the health care and societal perspective, it is highly relevant that the most optimal PPT treatment strategy is used. Therefore, more knowledge on optimized PPT strategies is necessary \[[@CR16], [@CR17]\].

It is conceivable that PPT may be optimized by using a standardized treatment, that is tailored to the patient's individual situation. Previous research has shown that targeting treatment using specific milestones, also called treat-to-target strategy, was found to assist physicians in disease management, by simplifying and facilitating disease management decisions \[[@CR18]\]. It is proven effective in improving clinical outcomes in various chronic conditions such as, cardiovascular disease and rheumatoid arthritis \[[@CR12], [@CR19], [@CR20]\]. However, milestones are currently not routinely used in PPT after TKA or THA to direct treatment. Another way via which care can be optimized is by use of a transmural care pathway, which includes a short stay (1--2 days) and acute (secondary care) and post-acute care (primary care). In TKA and THA these transmural pathways are known to result in less postoperative complications, shorter length of hospital stay and lower costs during hospital stay when compared to standard care (3--4 nights inpatient) \[[@CR21]--[@CR23]\]. Hence, a transmural pathway for PPT after TKA and THA linking all organizational aspects related to the continuum of TKA/THA care might also improve PPT. As such, we propose an individualized PPT intervention that is relatively standardized, yet the precise content, frequency and duration of treatment are determined by the acquisition of individualized, functional milestones. This research topic was prioritized on the research agenda of the Dutch Orthopaedic Association (NOV). Within this project, the NOV and the Royal Dutch Society for Physio therapy (KNGF) collaborate.

Trial objectives {#Sec2}
================

The aim of the present study is to evaluate the (cost-) effectiveness of a standardized, treat-to-target PPT strategy in TKA and THA patients compared to usual PPT. We hypothesize that with the standardized treat-to-target strategy better functional outcome can be achieved compared to usual care with lower costs (superiority study). The results of this study will be used to develop and implement a nationwide treatment strategy for PT after TKA/THA, and will be integrated in national guidelines of PTs and orthopedic surgeons.

Primary objective To assess whether the functional outcome of a standardized, personalized treat-to-target PT strategy after TKA and THA is superior to usual care PPT after 3 months follow-up.To assess whether a standardized, personalized treat-to-target PPT strategy is more cost-effective compared to usual care PPT after 12 months follow-up.

Secondary objective To assess whether the functional outcome of a standardized, personalized treat-to-target PPT strategy after TKA and THA is superior to usual care PPT during the follow-up of 12 months.To assess the difference in function, performance-based tests, pain and quality of life, as well as anchor questions, and satisfaction question; between both groups over time (6 weeks, 3,6,9 and 12 months) during the first year.

Methods/design {#Sec3}
==============

Study design and setting {#Sec4}
------------------------

We will use a multicenter, cluster randomized design. The 18 active including centers are; Alrijne hospital (Leiderdorp), Bergman Clinics (Rijswijk), Canisius Wilhelmina hospital (Nijmegen), Diakonessenhuis (Utrecht), Elisabeth-Tweesteden hospital (Tilburg), Erasmus MC University Medical Center (Rotterdam), HAGA hospital (Den Haag), hospital Gelderse Vallei (Ede), Leiden University MC (Leiden), Máxima MC (Eindhoven), MC Leeuwarden, Northwest Clinics (Alkmaar) OLVG (Amsterdam), Spaarne hospital (Hoofddorp), Tergooi hospital (Hilversum), University MC Groningen, University MC Maastricht and Zuyderland MC (Sittard). Lange Land hospital (Zoetermeer) and Reinier de Graaf Gasthuis (Delft) are participating in the study however they are not including patients. Reinier de Graaf is involved in developing the PPT protocol and a part of the patients of HAGA hospital will have surgery in Lange Land hospital.

In the intervention group, PT is delivered by selected primary care practices by specially trained PTs. The training is a physical training and will be given by the same project members. In the control group the choice to use PT and the primary care practice is left to the discretion of the orthopaedic surgeon and the patient. In the Netherlands, after TKA or THA, a referral from the orthopaedic surgeon is needed for the healthcare insurance. This referral is standardly given by discharge from the hospital.

The planned duration of the study is three years.

The study protocol was reviewed and approved by the Erasmus MC Medical Ethics Committee (registration code NL61763.078.17) and was registered in the Dutch Trial Registry (registration number NTR7129). In all participating hospitals, the local responsible authorities approved the conduct of the study.

Study population {#Sec5}
----------------

### Inclusion and exclusion criteria {#Sec6}

#### Inclusion {#FPar1}

Patients eligible for this trial are; a. patients with clinical and radiological knee or hip OA who are scheduled for a primary TKA or THA, b. willing to comply with the study protocol and c. providing written informed consent.

#### Exclusion {#FPar2}

Patients with a TKA or THA for a diagnosis other than OA; b. uncontrolled cardiovascular disease or hypertension; c. history of neuromuscular disorder that affects lower extremity function, d. terminal illness; e. planned replacement of another joint during study follow-up; f. not able to attend follow-up measurements; g. not able to attend the PPT in primary setting; h. serious psychiatric disorders; i. insufficient command of the Dutch language, spoken and/or written.

### Recruitment {#Sec7}

Patients who are scheduled for a primary TKA or THA in one of the participating hospitals and meet the eligibility criteria will be informed about the study by means of oral and written information. After written consent, baseline measurements are carried out. Recruitment is done by an orthopedic surgeon or researcher on his/her behalf.

Randomization {#Sec8}
-------------

To avoid contamination between treat-to-target intervention and usual care, randomization will take place on hospital level.

A randomization list was created by an independent statistician using Sealed Envelope (London, UK). Random permuted blocks sizes of 4, 6 and 8 were used, and randomization was stratified by type of hospital (academic or general). Upon request of the trial management, the independent statistician randomized a site using the randomization list and communicated the site allocated treatment strategy by e-mail. The trial management remained blind to the randomization throughout the study.

### Blinding {#Sec9}

The study is an open-label trial.

Intervention {#Sec10}
------------

### Development treat-to-target intervention {#Sec11}

The treat-to-target PPT is presented in the form of a transmural care pathway and was developed in four different phases knowingly, 1) an inventory phase, 2) development of the first draft, 3) development second draft, 4) finalizing treat-to-target PPT (Fig. [1](#Fig1){ref-type="fig"}). In the first phase, a literature study on the efficacy of PPT was done, in which guidelines regarding THA and TKA were taken into account. Also, an assessment of the existing perioperative treatment protocols in the Netherlands was conducted. Based on a selection of best practice (integrality and evidence based), one protocol was selected as the fundament for our treat-to-target intervention. In the second phase this protocol was adapted and supplemented using literature and guidelines. Hereafter the first concept of the protocol was discussed in an expert meeting of one primary and one secondary PT, a patient and orthopedic surgeons. In the third phase, the concept protocol was adjusted and details regarding the implementation in daily practice were added by 2 PTs who have extensive experience in the field of developing treatment protocols. The second concept of the protocol was again presented to the PTs, the patient and orthopedic surgeons who attended the first expert meeting for feedback. In the fourth and last phase, the protocol was adjusted based on the feedback of the expert panel resulting in final our treat-to-target intervention. This intervention consists of a preoperative assessment by the primary PT, secondary PPT and a comprehensive and personal transferal from the hospital PT including a Modified Iowa Levels of Assistance Scale (MILAS) score as a starting point of the secondary PPT. Fig. 1Development PATIO treat to target intervention care pathway

### Intervention arm: treat-to-target intervention {#Sec12}

First the necessity of PPT will be screened by a standardized assessment of the patient's health status, personal-, external factors and achievement of functional milestones. This assessment will be performed by the primary care PT in the first appointment after surgery (within 3 days after discharge from the hospital). Those needing PPT in primary care receive a standardized, personalized, time contingent program, focused on evidence-based components such as muscle strengthening and functional exercises. Exercises, selected by the PT, are available via an app or printed by the PT via Physitrack, an online available exercise program. The progress of functioning of the patient will be regularly evaluated regarding achievement of functional milestones. After reaching the milestones, PPT is ended and patients will receive a tailored advice with home-based exercises in combination with referral to exercise activities in the community.

### Control arm: usual care {#Sec13}

The use of PT and the choice of the physical therapist, is left to the discretion of the treating physician and the patient.

Assessments {#Sec14}
-----------

Patients will be asked to fill in questionnaires at baseline, and at 6 weeks, 3- (primary end-point), 6-, 9 and 12-months follow-up. Performance-based tests will be performed at baseline, 6- and 12 months (see Table [1](#Tab1){ref-type="table"} for an overview). In each participating hospitals an assessor will be trained by the coordinating researcher to perform these Performance-based tests. Table 1Overview of measurement PATIO studyTimepointAllocationEnrolmentPost-allocationClose-outRandomizationBaseline, at inclusion6 weeks,3, 6, 9 --months follow-up12-months follow-upEnrolment Eligibility screenX Informed consentXAllocationXInterventions *Intervention group: Treat to target*XX *Control group:Usual care*XXASSESSMENTS: *Demographic;* age, gender, side affected, BMI, education level, comorbidityX *HOOS-PS / KOOS - PS*XXX *OHS / OKS*XXX *NRS*XXX *AAQ*XX (only at 3 months)X *EQ 5-D5L*XXX *Satisfaction question*XX Cost-effectivenessXX *Performance-based tests*XX (only at 3 months)X  *(Serious) Adverse events*XX

### Patient characteristics {#Sec15}

At baseline the following patient characteristics will be obtained: age, sex, side affected, height, weight, education level, ethnical background, living situation (living alone, living with partner, living with partner and child (ren) and living with children), duration of complaints, previous surgery and existing comorbidities.

Primary outcomes {#Sec16}
----------------

### Physical functioning {#Sec17}

Physical functioning, assessed by the 5-item short version of the validated Dutch translation of the Hip disability and Osteoarthritis Outcome Score (HOOS) \[[@CR24], [@CR25]\] or the 7-item short version of the Dutch translation of the knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire \[[@CR26], [@CR27]\]. Function scores will be determined on a scale from 0 (severe impairments in function) to 100 (no impairments in function).

Direct and indirect costs {#Sec18}
-------------------------

Medical consumption (visits to health care providers and usage of prescribed or over the counter medication), absence from work or decreased productivity at work, and patient costs to be able to do cost-effectiveness analysis will be assessed with a questionnaire at 3,6,9 and 12 months postoperative. Our questionnaire is based on the questionnaire for Costs associated with Psychiatric Illness (TiC-P) from the institute of medical technology assessment \[[@CR28]\]. We have left out the irrelevant questions about psychiatric consultations. We added questions about PT consultation (frequency) and specified medication in use of pain medication.

Secondary outcomes {#Sec19}
------------------

### Pain and functioning {#Sec20}

#### Performance-based test {#FPar3}

Performance-based test as recommended by Osteoarthritis Research Society International (OARSI) \[[@CR29]\] namely, 30 s "chair-stand test", "40m walk test" and "stair negotiation" test, will be evaluated by the assessor. Assessors in all participating hospitals are trained in using a Dutch translated OARSI protocol. These tests will be performed at baseline, 3 months and 12 months.

Self-reported pain and function {#Sec21}
-------------------------------

### Numeric Rating Scale {#Sec22}

Hip and knee pain severity in rest and during activities in the past week will be assessed by the Numeric Rating Scale (NRS) \[[@CR30]\]. Scores range between 0 (no pain) and 10 (worst pain imaginable).

### Oxford Hip score / Oxford Knee Score {#Sec23}

Pain intensity and functional limitations in daily activities will be assessed by the Oxford Hip score (OHS) \[[@CR31]\] and the Oxford Knee Score (OKS) \[[@CR32]\]. Both consist of 12 questions; each question will be scored from 0 to 4 with 4 being the best outcome. Overall scores running from 0 to 48 with 48 being the best functional outcome.

### The Animated Activity Questionnaire (AAQ) {#Sec24}

Basic daily activity limitations will be assessed with the Animated Activity Questionnaire (AAQ) \[[@CR33]\] in which patients see video animations of 17 different basic daily life activities. These activities closely mimic real-life situations. For each activity, three to five different levels of difficulty in performing the activity are shown as video animations at the same time. The patient is asked to choose the video that best matches his or her own performance. Function scores will be determined on a scale from 0 (severe impairments in function) to 100 (no impairments in function). This video animated questionnaire will be assessed during the physical assessment appointment at baseline, 3 months and 12 months.

Quality of life {#Sec25}
---------------

### EuroQol-5D-5L {#Sec26}

Health-related quality of life will be assessed by the EuroQol-5D-5L (EQ-5D-5L) \[[@CR34]\]. This questionnaire consists of five domains (mobility, self-care, daily activities, pain/discomfort, and anxiety/depression) in which the patient can self-rate their severity of problems on a 5-point scale ranging from no problems to extreme problems or unable to perform the task.

Postoperative physical therapy (PPT) {#Sec27}
------------------------------------

Based on experiences in previous studies among physical therapists and patients \[[@CR14]\], we will retrospectively evaluate, in the intervention group, the care of the PPT and the compliance of the patients by asking the physical therapists and patients to fill out predefined report forms \[[@CR14]\]. The set of questions comprised the survey regarding PPT. In a random sample of 5% we will evaluate the status of the patient of the participating physical therapist what the given PPT care was (content, duration, frequency), and whether this agrees with the case report forms as described above.

In the control group we will also retrospectively evaluate the content, duration and frequency of the PPT with the same report forms.

Process evaluation {#Sec28}
------------------

### Anchor and satisfaction questions {#Sec29}

Two anchor questions ("How is your daily functioning changed since your surgery?"/ "How are your pain complaints changed since your surgery?", a patient satisfaction question on their surgery ("How satisfied are you (in general) about the results of your surgery?"), and a question regarding the given PPT ("How satisfied are you (in general) about the results of your PT treatment?") will be evaluated at all postoperative time points.

### (Serious) adverse events & dropout rates {#Sec30}

Any (S)AE will be communicated by the local researcher to the central researcher as soon as they become aware of it. The central researchers will report a SAE by the Centrale Commissie Mensgebonden Onderzoek (CCMO) via Toetsingonline within 7 (death or life threatening situations) or 15 (remaining SAE's) days. All drop-outs and protocol violations will be recorded.

An overview of the assessments can be found in Table [1](#Tab1){ref-type="table"}.

Sample size and power calculation {#Sec31}
=================================

Our primary research hypothesis is that the improvement in physical function in our "treat-to-target" intervention will be superior to the improvement in the usual care group at 3 months, measured by the HOOS-PS/KOOS-PS score.

The power calculation is based on the proof of superiority, and calculated for patients undergoing TKA and THA separately. The reported standard deviation (SD) of the KOOS-PS and HOOS-PS 3 months after physiotherapy in TKA and THA patients was 15.6 and 11.8, respectively \[[@CR35]--[@CR41]\]. For the intra cluster correlation coefficient we used an interclass correlation coefficient (ICC) of 0.06, which is generally reported in literature for hospital processes. To detect superiority of the treat-to-target PPT intervention to usual PPT we assessed the required sample size based on the following assumptions, a minimally clinical important difference (MCID) of 10 points, and a SD of 15.6. Since a MCID of the KOOS-PS and HOOS-PS after postoperative physiotherapy in TKA/THA patients is not yet available, a MCID was chosen based on expert opinion, namely 10 points on the KOOS-PS and HOOS-PS \[[@CR42], [@CR43]\].

Primary outcome {#Sec32}
---------------

We propose a cluster RCT (randomization on hospital level) with an intracluster correlation coefficient of 0.06 and in total 18 participating hospitals. Sample sizes of 90 in group one and 90 in group two, which were obtained by sampling 9 clusters with an average of 10 subjects each in group one (180 patients) and 9 clusters with an average of 10 subjects each in group two (180 patients), achieve 90% power to detect a difference between the group means of at least 10. The coefficient of variation of cluster sizes is 0,500. A two-sided t-test was used with a significance level of 0,05. This test used degrees of freedom based on the number of subjects. To account for a 25% of drop out 240 TKA and 240 THA patients will be needed.

Secondary outcomes {#Sec33}
------------------

We also assessed the needed numbers to detect superiority of the treat-to-target PPT intervention to usual PPT for the outcome improvement of pain severity as assessed by the NRS. Based on a MCID of 1 point on the NRS, and a SD of 2 the needed numbers were assessed. Sample sizes of 117 in group one and 117 in group two, which were obtained by sampling 9 clusters with an average of 13 subjects each in group one (234 patients) and 9 clusters with an average of 13 subjects each in group two (234 patients), achieve 91% power to detect a difference between the group means of at least 1. The SD of subjects is 1.7. The intracluster correlation coefficient is 0.06. The coefficient of variation of cluster sizes is 0.500. A two-sided t-test was used with a significance level of 0.05. This test used degrees of freedom based on the number of subjects. To account for a 25% of dropout,624 patients will be needed of which 312 TKA and 312 THA patients.

### Feasibility of recruitment {#Sec34}

Given the planned inclusion period of 12 months and the 18 centers participating and with an expected 100 inclusions a year (\~ 2 per week), accounting for patients who are not willing to participate, we expect to have sufficient numbers for our hypothesis. The length of the inclusion period is based on the inclusion rate of the assumed slowest including hospitals (UMCs).

### Data management {#Sec35}

All data are handled confidentially and anonymized in compliance with the Dutch Personal Data Protection Act ("Wet Bescherming Persoonsgegevens"). Questionnaires are collected digitally, and the patient study data are stored in a coded way using secured data management software system Castor EDC \[[@CR44]\]. In case an email address is not available, a paper case report form is sent to the patient. When patients fill in their questionnaires on paper, documentation is stored in the investigator site file. Each patient is assigned a random study number that is used for all documentation, study reports and publications. The key to this study number is handled by an independent researcher. All data will be stored during the study period in Castor EDC, after the study is finished the data will be stored for 15 years. Documentation, such as questionnaires filled in on paper and signed informed consent forms, stored in the investigator site file will be stored at each site.

Statistical analysis {#Sec36}
====================

The results will be analyzed separately for TKA and THA. We will analyze patients as treated.

Primary outcome measure {#Sec37}
-----------------------

The difference between both groups in change of KOOS-PS/HOOS-PS between baseline and 3 months follow-up score will be used as primary outcome. Patients will be analyzed as treated.

The primary analyses will be performed by using mixed models (change in KOOS-PS/HOOS-PS during 3 months as dependent and intervention as independent variable). Change between baseline and 3 months follow-up score will be used as primary outcome. Hospital variable will be used to indicate the correlation structure in the model. Adjustments will take place for baseline values of KOOS-PS/HOOS-PS. Of variables of which a priori is known that they are associated with the change in KOOS/HOOS-PS, based on previous studies or based on a strong clinical rationale will be considered as covariates in the primary analysis. These covariates are age, gender, BMI, and surgical approach in THA (anterior, lateral and postero-lateral). The assumptions of constant variance and linear relationships will be assessed. Should any of these assumptions seriously fail then transformation of the dependent or independent variable(s) (where applicable) will be used. The choice of which transformation (e.g. square root, logarithm) will be used will be based on the specific distribution of the residuals.

Secondary outcomes {#Sec38}
------------------

By using repeated measures mixed models analyses the course of the secondary outcome(s) over time of both interventions will be compared. The following time points will be used, baseline and follow-up measurements at 6 weeks, 3, 6, 9, 12 months.

Change in secondary outcomes will be used as dependent variable. As secondary outcomes will be used: KOOS-PS/HOOS-PS; OKS/OHS, NRS, AAQ, EuroQol-5D-5L, performance-based test and the anchor and satisfaction questions.

### Economic evaluation {#Sec39}

The economic evaluation will consist of a cost-utility analysis from a societal perspective (costs per QALY), based on patient reports and with an undiscounted one-year time horizon. Average costs and outcomes will be statistically compared using net-benefit analysis, with multiple imputation to account for missing data. Quality-adjusted life years (QALYs) will be estimated using the Dutch tariff for the quarterly EQ-5D-5L measurements. Societal costs will include healthcare costs, patient and family costs, and productivity costs. The timing, contents, frequency and duration of PPT will be measured using the study registrations. Other healthcare use and productivity will be reported by patients using quarterly questionnaires (including general practitioner visits, outpatient visits, hospital days, medication, home and informal care, patient costs, absence from work, and productivity while at (unpaid) work). Healthcare will be valued using reference prices obtained from the Dutch guidelines for economic evaluations in healthcare, including time and travel costs. Sensitivity analysis will be performed on the cost perspective (healthcare instead of societal perspective), the valuation of productivity (human capital instead of friction cost approach) and the utility measure used to calculate QALYs (Visual analogue scale for health (with power transformation) instead of Dutch EQ-5D-5L tariff).

In addition to the CUA, a budget impact analysis (BIA) will be performed. In a cost-calculator spreadsheet model, budget impact will be evaluated from the perspectives of the Dutch 'Budgettair Kader Zorg' (BKZ), health insurers, and the different care providers. The analysis will take into account the current mix of treatments, with prices appropriate for the perspective, a 4-year time-horizon and different scenarios for the rate of uptake.

Discussion {#Sec40}
==========

The PATIO trial is, to our knowledge, the first study that analyses the (cost-)effectiveness of a standardized, personalized postoperative physiotherapy protocol compared to usual postoperative care in patients with OA receiving TKA/THA.

Given the large variation in the provision of PPT, which seems to be not or weakly associated with patient characteristics, a more standardized, personalized approach seems warranted. The planned randomized controlled trial, with an economic evaluation will answer the question whether patients who receive a treat-to-target intervention recover with better functional outcomes against lower costs compared to the usual care PPT. From the health care and societal perspective it is extremely relevant that the most optimal PPT treatment strategy is used, as it concerns about 1.66 (THA) and 1.26 (TKA) per 1.000 people per year in western countries \[[@CR16]\].

Besides measuring the (cost-) effectiveness of a treat-to-target PPT we also asses a broader range of health aspects (e.g. physical function, pain, comorbidities, perceived health and mental factors, information on insurance and satisfaction level of the results of their surgery and the PT) because several factors can influence the individual recovery after TKA/THA.

Strengths of the study include the nationwide multicenter design, supported by multiple involved professions. PTs are trained to work with the treat-to-target protocol. PTs who are trained on the protocol will unconsciously adapt their usual care treatment. To avoid contamination between the treat-to-target PPT and the usual care PPT a cluster RCT design was chosen. When a PT is trained by the treat-to-target protocol he/she will only treat patients in the intervention group. Since the power and precision of a cluster randomized trial is lower than an individually randomized trial, our study needs more participants to obtain the same statistical power. Another possible limitation of the study is the variation in surgical techniques which may have a different effect in the first months of the revalidation period of the patient.

The results of this study will address an important evidence gap and will have significant impact on the daily practice of the physiotherapist.

Trial status {#Sec41}
============

The study inclusion has started in August 2018 and is still ongoing.
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